The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Neuroinflammation in Alzheimer's disease and prion disease
Abstract
Alzheimer's disease (AD) and prion disease are characterized neuropathologically by extracellular deposits of Aβ and PrP amyloid fibrils, respectively. In both disorders, these cerebral amyloid deposits are co‐localized with a broad variety of inflammation‐related proteins (complement factors, acute‐phase protein, pro‐inflammatory cytokines) and clusters of activated microglia. The present data suggest that the cerebral Aβ and PrP deposits are closely associated with a locally induced, non‐immune‐mediated chronic inflammatory response. Epidemiological studies indicate that polymorphisms of certain cytokines and acute‐phase proteins, which are associated with Aβ plaques, are genetic risk factors for AD. Transgenic mice studies have established the role of amyloid associated acute‐phase proteins in Alzheimer amyloid formation. In contrast to AD, there is a lack of evidence that cytokines and acute‐phase proteins can influence disease progression in prion disease. Clinicopathological and neuroradiological studies have shown that activation of microglia is a relatively early pathogenetic event that precedes the process of neuropil destruction in AD patients. It has also been found that the onset of microglial activation coincided in mouse models of prion disease with the earliest changes in neuronal morphology, many weeks before neuronal loss and subsequent clinical signs of disease. In the present work, we review the similarities and differences between the involvement of inflammatory mechanisms in AD and prion disease. We also discuss the concept that the demonstration of a chronic inflammatory‐like process relatively early in the pathological cascade of both diseases suggests potential therapeutic strategies to prevent or to retard these chronic neurodegenerative disorders. GLIA 40:232–239, 2002. © 2002 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388 · cited 2×
“…for the classical NSAIDs that are known to inhibit both COX-1 and COX-2 but which have other, non-COX-mediated, modes of action, such as activation of nuclear receptor peroxisome proliferator-activated receptor- (PPAR ) and lowering A 42 production (Landreth et al., 2001; Weggen et al., 2001).”
BackgroundMcGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367 · cited 2×
“The idea that the neuroinflammatory response is an interesting therapeutic target for treatment with antiinflammatory drugs was also strongly supported by epidemiological studies showing that the use of classical NSAIDS can prevent or retard AD (McGeer et al., 1996; in t’ Veld et al., 2001).”
BackgroundActivation of microglial cells by β-amyloid protein and interferon-γ
Meda, L., Cassatella, M. A., Szendrei, G. I., Otvos, L., Baron, P., Villalba, M., Ferrari, D., & Rossi, F. (1995) · Nature · doi:10.1038/374647a0 · Cited by 1,314
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196 · cited 2×
“The idea that the neuroinflammatory response is an interesting therapeutic target for treatment with antiinflammatory drugs was also strongly supported by epidemiological studies showing that the use of classical NSAIDS can prevent or retard AD (McGeer et al., 1996; in t’ Veld et al., 2001).”
BackgroundIn-vivo measurement of activated microglia in dementia
Cagnin, A., Brooks, D. J., Kennedy, A. M., Gunn, R. N., Myers, R., Turkheimer, F. E., Jones, T., & Banati, R. B. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05625-2 · Cited by 1,054
Ma, J., Yee, A., Brewer, H. B., Das, S., & Potter, H. (1994) · Nature · doi:10.1038/372092a0 · Cited by 871 · cited 1×
“Furthermore, when the amyloid plaque associated 1-antichymotrypsin (ACT) or apolipoprotein E (ApoE) are added to preparations of synthetic A peptide in vitro, they promote the polymerization of A into amyloid filaments (Ma et al., 1994).”
BackgroundLack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
Bales, K. R., Verina, T., Dodel, R. C., Du, Y., Altstiel, L., Bender, M., Hyslop, P., Johnstone, E. M., Little, S. P., Cummins, D. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1197-263 · Cited by 830
Complement activation by beta-amyloid in Alzheimer disease.
Rogers, J., Cooper, N. R., Webster, S., Schultz, J., McGeer, P. L., Styren, S. D., Civin, W. H., Brachova, L., Bradt, B., & Ward, P. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.21.10016 · Cited by 817
Cited by
Immune attack: the role of inflammation in Alzheimer disease
Heppner, F. L., Ransohoff, R. M., & Becher, B. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3880 · Cited by 2,134
P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury
Tsuda, M., Shigemoto-Mogami, Y., Koizumi, S., Mizokoshi, A., Kohsaka, S., Salter, M. W., & Inoue, K. (2003) · Nature · doi:10.1038/nature01786 · Cited by 1,563
Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism
Block, M. L., & Hong, J.-S. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.06.004 · Cited by 1,557
Inflammation in neurodegenerative diseases
Amor, S., Puentes, F., Baker, D., & Van Der Valk, P. (2010) · Immunology · doi:10.1111/j.1365-2567.2009.03225.x · Cited by 1,355
Impairment of Glymphatic Pathway Function Promotes Tau Pathology after Traumatic Brain Injury
Iliff, J. J., Chen, M. J., Plog, B. A., Zeppenfeld, D. M., Soltero, M., Yang, L., Singh, I., Deane, R., & Nedergaard, M. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3020-14.2014 · Cited by 1,159
Three or more routes for leukocyte migration into the central nervous system
Ransohoff, R. M., Kivisäkk, P., & Kidd, G. (2003) · Nature Reviews Immunology · doi:10.1038/nri1130 · Cited by 1,052
Microglia and neuroinflammation: a pathological perspective
Streit (2004) · Journal of Neuroinflammation · doi:10.1186/1742-2094-1-14 · Cited by 1,039
Neuroinflammation induced by lipopolysaccharide causes cognitive impairment in mice
Zhao, J., Bi, W., Xiao, S., Lan, X., Cheng, X., Zhang, J., Lu, D., Wei, W., Wang, Y., Li, H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-42286-8 · Cited by 896
Neuropathic pain and spinal microglia: a big problem from molecules in ‘small’ glia
Tsuda, M., Inoue, K., & Salter, M. W. (2005) · Trends in Neurosciences · doi:10.1016/j.tins.2004.12.002 · Cited by 790
Lee, J. W., Lee, Y. K., Yuk, D. Y., Choi, D. Y., Ban, S. B., Oh, K. W., & Hong, J. T. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-37 · Cited by 772
Does neuroinflammation fan the flame in neurodegenerative diseases?
Frank-Cannon, T. C., Alto, L. T., McAlpine, F. E., & Tansey, M. G. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-47 · Cited by 751
Matrix metalloproteinases in the brain and blood–brain barrier: Versatile breakers and makers
Rempe, R. G., Hartz, A. M., & Bauer, B. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16655551 · Cited by 721
Common mechanisms of amyloid oligomer pathogenesis in degenerative disease
Glabe, C. G. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.04.017 · Cited by 569
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
Role of the Toll-Like Receptor 4 in Neuroinflammation in Alzheimer’s Disease
Walter, S., Letiembre, M., Liu, Y., Heine, H., Penke, B., Hao, W., Bode, B., Manietta, N., Walter, J., Schulz-Schüffer, W., et al. (2007) · Cellular Physiology and Biochemistry · doi:10.1159/000110455 · Cited by 543
Rossignol, D. A., & Frye, R. E. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.165 · Cited by 543
Edison, P., Archer, H. A., Gerhard, A., Hinz, R., Pavese, N., Turkheimer, F. E., Hammers, A., Tai, Y. F., Fox, N., Kennedy, A., et al. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.08.001 · Cited by 513
“…which in turn release potentially neurotoxic substances, such as nitric oxide, pro-inflammatory cytokines, complement proteins, and other inflammatory mediators, resulting in tau phosphorylation and neurodegenerative changes (Akiyama et al., 2000; Eikelenboom et al., 2002; McGeer and McGeer, 2001).”
BackgroundMicroglia Biology in Health and Disease
Garden, G. A., & Möller, T. (2006) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-006-9015-5 · Cited by 496
MicroRNA-146a: A Dominant, Negative Regulator of the Innate Immune Response
Saba, R., Sorensen, D. L., & Booth, S. A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00578 · Cited by 427
Congo red and protein aggregation in neurodegenerative diseases
Frid, P., Anisimov, S. V., & Popovic, N. (2007) · Brain Research Reviews · doi:10.1016/j.brainresrev.2006.08.001 · Cited by 402
Inflammation and Alzheimer’s disease
Lee, Y.-J., Han, S. B., Nam, S.-Y., Oh, K.-W., & Hong, J. T. (2010) · Archives of Pharmacal Research · doi:10.1007/s12272-010-1006-7 · Cited by 396
Toll‐like receptors in central nervous system glial inflammation and homeostasis
Kielian, T. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.20767 · Cited by 361
Microglia and Alzheimer's disease pathogenesis
Streit, W. J. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20093 · Cited by 335
The function of microglia through purinergic receptors: Neuropathic pain and cytokine release
Inoue, K. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.07.001 · Cited by 328
McHugh, D., Hu, S. S., Rimmerman, N., Juknat, A., Vogel, Z., Walker, J. M., & Bradshaw, H. B. (2010) · BMC Neuroscience · doi:10.1186/1471-2202-11-44 · Cited by 323
Microglia actions in Alzheimer's disease
Prokop, S., Miller, K. R., & Heppner, F. L. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1182-x · Cited by 291
Balez, R., Steiner, N., Engel, M., Muñoz, S. S., Lum, J. S., Wu, Y., Wang, D., Vallotton, P., Sachdev, P., O’Connor, M., et al. (2016) · Scientific Reports · doi:10.1038/srep31450 · Cited by 278
Oxidative and Antioxidative Potential of Brain Microglial Cells
Dringen, R. (2005) · Antioxidants & Redox Signaling · doi:10.1089/ars.2005.7.1223 · Cited by 266
Takeuchi, H., Mizuno, T., Zhang, G., Wang, J., Kawanokuchi, J., Kuno, R., & Suzumura, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413863200 · Cited by 285
The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases
Rey, N. L., Wesson, D. W., & Brundin, P. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.12.013 · Cited by 257
Aungst, S. L., Kabadi, S. V., Thompson, S. M., Stoica, B. A., & Faden, A. I. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2014.75 · Cited by 253
TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice
Frank, S., Burbach, G. J., Bonin, M., Walter, M., Streit, W., Bechmann, I., & Deller, T. (2008) · Glia · doi:10.1002/glia.20710 · Cited by 247
“Cerebral amyloid-b deposits are accompanied by a reactive glial response with the recruitment of microglia being a hallmark (Aisen, 1997; Akiyama et al., 2000; Benveniste et al., 2001; Eikelenboom et al., 2002; Hauwel et al., 2005).”
BackgroundUnterberger, U., Höftberger, R., Gelpi, E., Flicker, H., Budka, H., & Voigtländer, T. (2006) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/01.jnen.0000218445.30535.6f · Cited by 237
Vukic, V., Callaghan, D., Walker, D., Lue, L.-F., Liu, Q. Y., Couraud, P.-O., Romero, I. A., Weksler, B., Stanimirovic, D. B., & Zhang, W. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.12.007 · Cited by 232
“…such as reactive oxygen and nitrogen species, pro-inflammatory cytokines, chemokines, complement, and other inflammatory mediators that bring about neurodegenerative changes in Alzheimer's disease (Akiyama et al., 2000; Eikelenboom et al., 2002; McGeer and McGeer, 2001, 2004; Rogers et al., 2002).”
BackgroundGasparini, L., Ongini, E., & Wenk, G. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02743.x · Cited by 226
Macrophages and microglia in central nervous system injury: are they helpful or harmful?
Schwartz, M. (2003) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200304000-00001 · Cited by 207
“…in the presence of the activated innate immune cells, leading observers to assume that these were the cells causing the ongoing spread of damage (Eikelenboom et al., 2002; Lue and Walker, 2002; Magnus et al., 2002; McGeer and McGeer, 2002; Polazzi and Contesabile, 2002; Srebro and Dziobek,…”
BackgroundPolyunsaturated fatty acids, neuroinflammation and well being
Layé, S. (2010) · Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA) · doi:10.1016/j.plefa.2010.02.006 · Cited by 167
Brahmi (Bacopa monnieri): An ayurvedic herb against the Alzheimer's disease
Dubey, T., & Chinnathambi, S. (2019) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2019.108153 · Cited by 151
Abutbul, S., Shapiro, J., Szaingurten‐Solodkin, I., Levy, N., Carmy, Y., Baron, R., Jung, S., & Monsonego, A. (2012) · Glia · doi:10.1002/glia.22343 · Cited by 122
Imaging of microglia in patients with neurodegenerative disorders
Politis, M. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00096 · Cited by 111
CD163 Identifies a Unique Population of Ramified Microglia in HIV Encephalitis (HIVE)
Roberts, E. S., Masliah, E., & Fox, H. S. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.12.1255 · Cited by 100
“AD is not generally characterized as an inflammatory disorder because there is little to no infiltration of leukocytes (27), however, microglia activation is found from early on in the disease, which has caused many researchers to characterize it as potentially inflammatory in nature (28, 29).”
BackgroundLiu, Y.-J., Guo, D.-W., Tian, L., Shang, D.-S., Zhao, W.-D., Li, B., Fang, W.-G., Zhu, L., & Chen, Y.-H. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.03.024 · Cited by 92
Marlatt, M. W., Bauer, J., Aronica, E., van Haastert, E. S., Hoozemans, J. J. M., Joels, M., & Lucassen, P. J. (2014) · Neural Plasticity · doi:10.1155/2014/693851 · Cited by 83
“Microglia are broadly implicated in AD [4, 8, 19] and have, for example, been found to migrate to A 𝛽 lesions 2 Neural Plasticity [20–23], degrade A 𝛽 peptide in vitro [24, 25], and participate in the clearance of A 𝛽 from the brain [26].”
BackgroundSelf-citationRamírez, G., Toro, R., Döbeli, H., & von Bernhardi, R. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.01.007 · Cited by 60
“However, glial cells also release a variety of molecules, such as oxygen reactive species (ROS), nitrogen intermediaries, pro-inflammatory mediators like cytokines and chemokines, complement factors, etc., that could induce cell damage (Akiyama et al., 2000; Eikelenboom et al., 2002).”
BackgroundJin, P., Kim, J.-A., Choi, D.-Y., Lee, Y.-J., Jung, H. S., & Hong, J. T. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-2 · Cited by 59
Yang, Y.-M., Shang, D.-S., Zhao, W.-D., Fang, W.-G., & Chen, Y.-H. (2013) · Neurochemical Research · doi:10.1007/s11064-013-1138-5 · Cited by 57
Pro- and anti-inflammatory cytokines in the CSF of patients with creutzfeldt-jakob disease.
Stoeck, K., Bodemer, M., & Zerr, I. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2005.10.008 · Cited by 49
Accelerated Prion Replication in, but Prolonged Survival Times of, Prion-Infected CXCR3−/−Mice
Riemer, C., Schultz, J., Burwinkel, M., Schwarz, A., Mok, S. W. F., Gültner, S., Bamme, T., Norley, S., van Landeghem, F., Lu, B., et al. (2008) · Journal of Virology · doi:10.1128/jvi.01371-08 · Cited by 45
Álvarez, M., Rivas, L., Lacruz, C., & Toledano, A. (2015) · Glia · doi:10.1002/glia.22751 · Cited by 35
Rezaie, P., Pontikis, C. C., Hudson, L., Cairns, N. J., & Lanto, P. L. (2005) · Journal of Histochemistry & Cytochemistry · doi:10.1369/jhc.4a6551.2005 · Cited by 32
Walker, D. J., Zimmer, C., Larriva, M., Healy, S. D., & Spencer, K. A. (2019) · Journal of Experimental Biology · doi:10.1242/jeb.187039 · Cited by 15
Song, P.-J., Barc, C., Arlicot, N., Guilloteau, D., Bernard, S., Sarradin, P., Chalon, S., Garreau, L., Kung, H. F., Lantier, F., et al. (2010) · Molecular Imaging and Biology · doi:10.1007/s11307-010-0321-1 · Cited by 11
The associations of cerebrospinal fluid ApoE and C1q with Alzheimer's disease biomarkers
Lin, Y.-J., Liu, Y., Sheng, Z.-H., Fu, Y., Ma, L.-Z., Zhang, Z.-H., Wang, L.-Y., Huang, L.-Y., Liu, M., Wang, Z.-T., et al. (2025) · Journal of Alzheimer’s Disease · doi:10.1177/13872877251320419 · Cited by 3
Metadata
- Authors
- Eikelenboom, P., Bate, C., Van Gool, W. A., Hoozemans, J. J. M., Rozemuller, J. M., Veerhuis, R., & Williams, A.
- Venue
- Glia
- Publisher
- Wiley
- Published
- 2002-10-04
- Volume
- 40
- Issue
- 2
- Pages
- 232-239
- ISSN
- 0894-1491 (ISSN-L)
- 1098-1136
- OpenAlex
- W2089701069
- Cited by
- 405
- References
- 63
- FWCI
- 11.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.